IDH1 and anemia (phenotype): Therefore, enasidenib may be a promising therapeutic agent for improvement of anemia in a wide array of clinical contexts outside of IDH1/2mt cancers.89 This mechanism is supplementary to the mtIDH1/2-inhibitor-induced restoration of the abovementioned deficiency of succinyl-CoA in IDH1/2mt myeloid progenitor cells, a critical component for heme biosynthesis.51